Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

EURETINA: PulseSight Therapeutics to Present Results of Phase 1 clinical trial of PST-611 ...

16 September 2026 · By · Wire by Fusion42

Published

16 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at firstwordpharma.com →

◆ Verified

Fusion42 · 16 September 2026 · Fusion42 review

PulseSight Therapeutics announced positive Phase 1 trial results for PST-611, a non-viral gene therapy for dry Age-related Macular Degeneration (AMD) and Geographic Atrophy, demonstrating safety, tolerability, and early efficacy signals in 6 patients with no approved treatments currently in Europe.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech startup focused on retinal diseases now sees a fresh opening as non-viral gene therapies prove safe with early vision improvements reported. The unmet need in dry AMD and GA means this therapy could reshape treatment options and investor interest in ocular gene therapies.

◆ Coverage

1 source · 16 Sep 2026

◆ Related on Wire

◆ Topics

Biotechgene-therapyophthalmologyclinical-trialdry-amdgeographic-atrophy